๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-08-03

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (NCT07664553)

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)

๐ŸŸข Recruiting Phase3 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: AstraZeneca

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)

Who can join: Review the eligibility criteria below.

Location: Research Site โ€” Little Rock, Arkansas

Age range: 18 Years

๐Ÿงช Interventions in This Study

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (132 Sites)

Showing the first 25 of 132 sites.

  • Research Site โ€” Little Rock, Arkansas
  • Research Site โ€” Sacramento, California
  • Research Site โ€” Aurora, Colorado
  • Research Site โ€” DeLand, Florida
  • Research Site โ€” Doral, Florida
  • Research Site โ€” Ocoee, Florida
  • Research Site โ€” Decatur, Georgia
  • Research Site โ€” Potomac, Maryland
  • Research Site โ€” Brooklyn, New York
  • Research Site โ€” Cary, North Carolina
  • Research Site โ€” Morehead City, North Carolina
  • Research Site โ€” Myrtle Beach, South Carolina
  • Research Site โ€” Memphis, Tennessee
  • Research Site โ€” Houston, Texas
  • Research Site โ€” Round Rock, Texas
  • Research Site โ€” San Antonio, Texas
  • Research Site โ€” Renton, Washington
  • Research Site โ€” Campbelltown,
  • Research Site โ€” East Toowoomba,
  • Research Site โ€” Heidelberg Heights,
  • Research Site โ€” Parkville,
  • Research Site โ€” St Leonards,
  • Research Site โ€” Dupnitsa,
  • Research Site โ€” Kozloduy,
  • Research Site โ€” Plovdiv,

๐Ÿ“ž Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—